Epidemiology and trends in the antibiotic susceptibilities of Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region, 2010–2013

International Journal of Antimicrobial Agents

Volumn 49, Issue 6, 2017, Pages 734-739

  Chang, Ya Ting ^a,b   Coombs, Geoffrey ^c   Ling, Thomas ^d   Balaji, V ^e   Rodrigues, Camilla ^f   Mikamo, Hiroshige ^g   Kim, Min Ja ^h   Rajasekaram, Datin Ganeswrie ⁱ   Mendoza, Myrna ^j   Tan, Thean Yen ^k   Kiratisin, Pattarachai ^l   Ni, Yuxing ^m   Barry, Weinman ⁿ   Xu, Yingchun ^o   Chen, Yen Hsu ^a,b,p   Hsueh, Po Ren ^q  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c ROYAL PERTH HOSPITAL   (Australia)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e CHRISTIAN MEDICAL COLLEGE   (India)

^f P D HINDUJA NATIONAL HOSPITAL   (India)

^g AICHI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^h Korea University College of Medicine   (South Korea)

ⁱ HOSPITAL SULTANAH AMINAH   (Malaysia)

^j PHILIPPINE GENERAL HOSPITAL   (Philippines)

^k CHANGI GENERAL HOSPITAL   (Singapore)

^l MAHIDOL UNIVERSITY   (Thailand)

^m SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

ⁿ MERCK RESEARCH LABORATORIES   (United States)

^o PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^p NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^q NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

more..

Author keywords

Antimicrobial susceptibility; Asia Pacific region; Epidemiology; Extended spectrum lactamase; Gram negative bacilli; Intra abdominal infection

Indexed keywords

AMIKACIN; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ACINETOBACTER CALCOACETICUS-BAUMANNII COMPLEX; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRALIA; BACTERIUM ISOLATE; CHINA; CITROBACTER FREUNDII; CONTROLLED STUDY; DRUG EFFICACY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; GRAM NEGATIVE BACTERIUM; HONG KONG; HOSPITAL ADMISSION; HUMAN; IN VITRO STUDY; JAPAN; KAZAKHSTAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MALAYSIA; MORGANELLA MORGANII; NEW ZEALAND; NONHUMAN; PHILIPPINES; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; SINGAPORE; SOUTH KOREA; TAIWAN; THAILAND; TREND STUDY; VIET NAM; ASIA; DRUG EFFECTS; GRAM NEGATIVE INFECTION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PACIFIC ISLANDS; PROSPECTIVE STUDY;

ANTI-BACTERIAL AGENTS; ASIA; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTRAABDOMINAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; PACIFIC ISLANDS; PROSPECTIVE STUDIES;

EID: 85018976801     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2017.01.030     Document Type: Article

References (20)

1. Armstrong, C., Updated guideline on diagnosis and treatment of intra-abdominal infections. Am Fam Phys 82 (2010), 694–709.
2. Cattan, P., Yin, D.D., Sarfati, E., Lyu, R., De Zelicourt, M., Fagnani, F., Cost of care for inpatients with community-acquired intra-abdominal infections. Eur J Clin Microbiol Infect Dis 21 (2002), 787–793.
3. Vardakas, K.Z., Tansarli, G.S., Rafailidis, P.I., Falagas, M.E., Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 67 (2012), 2793–2803.
4. Hsueh, P.R., Badal, R.E., Hawser, S.P., Hoban, D.J., Bouchillon, S.K., Ni, Y., et al. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Int J Antimicrob Agents 36 (2010), 408–414.
5. Hsueh, P.R., Study for Monitoring Antimicrobial Resistance Trends (SMART) in the Asia-Pacific region, 2002–2010. Int J Antimicrob Agents 40:Suppl. (2012), S1–3.
6. Liu, Y.M., Chen, Y.S., Toh, H.S., Huang, C.C., Lee, Y.L., Ho, C.M., et al. In vitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents 40:Suppl. (2012), S11–17.
7. Morrissey, I., Hackel, M., Badal, R., Bouchillon, S., Hawser, S., Biedenbach, D., A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel) 6 (2013), 1335–1346.
8. Jean, S.S., Hsueh, P.R., Group, S.A.-P., Distribution of ESBLs, AmpC β-lactamases and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal and urinary tract infections in the Asia-Pacific region during 2008–14: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 72 (2017), 166–171.
9. Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. Document M100-S23. 2013, CLSI, Wayne, PA.
10. Hawser, S.P., Bouchillon, S.K., Hoban, D.J., Badal, R.E., Hsueh, P.R., Paterson, D.L., Emergence of high levels of extended-spectrum-β-lactamase-producing Gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrob Agents Chemother 53 (2009), 3280–3284.
11. Ko, W.C., Hsueh, P.R., Increasing extended-spectrum β-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the SMART Study 2002–2006. J Infect 59 (2009), 95–103.
12. Collins, V.L., Marchaim, D., Pogue, J.M., Moshos, J., Bheemreddy, S., Sunkara, B., et al. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 56 (2012), 2173–2177.
13. Hoban, D.J., Badal, R., Bouchillon, S., Hackel, M., Kazmierczak, K., Lascols, C., et al. In vitro susceptibility and distribution of β-lactamases in Enterobacteriaceae causing intra-abdominal infections in North America 2010–2011. Diagn Microbiol Infect Dis 79 (2014), 367–372.
14. Sheng, W.H., Badal, R.E., Hsueh, P.R., Program, S., Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 57 (2013), 2981–2988.
15. Marchaim, D., Sunkara, B., Lephart, P.R., Gudur, U.M., Bhargava, A., Mynatt, R.P., et al. Extended-spectrum β-lactamase producers reported as susceptible to piperacillin–tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests. Infect Control Hosp Epidemiol 33 (2012), 853–855.
16. Sader, H.S., Hsiung, A., Fritsche, T.R., Jones, R.N., Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. Diagn Microbiol Infect Dis 57 (2007), 341–344.
17. Schwaber, M.J., Carmeli, Y., Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA 300 (2008), 2911–2913.
18. Rodriguez-Bano, J., Navarro, M.D., Retamar, P., Picon, E., Pascual, A., β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 54 (2012), 167–174.
19. Tamma, P.D., Han, J.H., Rock, C., Harris, A.D., Lautenbach, E., Hsu, A.J., et al. Carbapenem therapy is associated with improved survival compared with piperacillin–tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis 60 (2015), 1319–1325.
20. Rennie, R.P., Jones, R.N., Effects of breakpoint changes on carbapenem susceptibility rates of Enterobacteriaceae: results from the SENTRY Antimicrobial Surveillance Program, United States, 2008 to 2012. Can J Infect Dis Med Microbiol 25 (2014), 285–287.